FMP
NASDAQ
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
8.95 USD
0.01 (0.112%)
Valuation Date:
May 3, 2024 4:00 PM
Share Price on Valuation Date
$8.95
Stock Beta
1.024
Shares Outstanding
2592434